Home » Topics » Disease categories and therapies » Urology

Urology
RSS

Glaxo Wellcome claims 5alpha-reductase inhibitors for BPH

Nov. 19, 1996

OP-1 effective in renal failure

Nov. 15, 1996

Clinical trial program for RenaGel continues on schedule

Nov. 8, 1996

Synaptic, Merck extend BPH collaboration

Nov. 8, 1996

CV Therapeutics reports novel adenosine antagonist

Nov. 8, 1996

Potential use of phytopharmaceutical compounds for BPH

Nov. 1, 1996

Muscarinic antagonists from Yamanouchi

Oct. 25, 1996

New alternative available for BPH

Oct. 18, 1996

Merck persists in the search for BPH therapeutics

Oct. 18, 1996

Renal-urologic drugs in development at Yamanouchi

Oct. 11, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 22, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.